title: Intracerebral infusion of a second-generation ciliary neurotrophic factor reduces neuronal loss in rat striatum following experimental intracerebral hemorrhage.
abstract: Neuronal and glial cell death in the striatum of a rat model of collagenase-induced intracerebral hemorrhage begins at 1 day and continues for at least 3 weeks. We hypothesized that administration of a neurotrophic agent would reduce neuronal loss in this experimental model. Because it has been shown to protect striatal neurons against excitotoxic injury, a second-generation ciliary neurotrophic factor (CNTF) (AXOKINE) was administered by continuous intracerebral infusion (2 microg/day) beginning 28 h after hemorrhage and continuing for 2 weeks. Magnetic resonance imaging showed that the hematoma size was comparable in control and treated rats prior to treatment. Counts of medium-sized striatal neurons within 320 microm of the hematoma 8 weeks after the hemorrhage revealed a slight but statistically significant benefit with a 42.5% loss in treated rats compared to 51.7% loss in controls. The results suggest that AXOKINE might be protective of striatal neurons in the vicinity of a hemorrhagic lesion.
authors.affiliation: Department of Pathology, University of Manitoba, D212-770 Bannatyne Avenue, Winnipeg, Manitoba, Canada R3E 0W3. delbigi@cc.umanitoba.ca
authors.forename: M R
authors.initials: MR
authors.lastname: Del Bigio
authors.forename: H J
authors.initials: HJ
authors.lastname: Yan
authors.forename: M
authors.initials: M
authors.lastname: Xue
mesh_terms: D000818:Animals; D020145:Basal Ganglia Hemorrhage / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D016923:Cell Death / Q000187:drug effects* / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002543:Cerebral Hemorrhage / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D020934:Ciliary Neurotrophic Factor / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D020287:In Situ Nick-End Labeling; D008297:Male; D009336:Necrosis; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D020934:Ciliary Neurotrophic Factor; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D011994:Recombinant Proteins; C118937:axokine